Announcements
- Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate
- Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study
- Addex Announces Participation in the H.C. Wainwright Global Investment Conference
- Addex Announces Participation in the 22nd Bio€quity Europe Conference
- Addex Shareholders Approve All Resolutions at Annual General Meeting
- Addex Reports Q1 2022 Financial Results
- Addex to Present at the Swiss Biotech Day 2022
- Addex to Present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference
- Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study
- Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders
More ▼
Key statistics
On Friday, Addex Therapeutics Ltd (APE0:STU) closed at 1.11, 15.03% above the 52 week low of 0.965 set on Jun 29, 2022.
52-week range
Markit short selling activity
Open | 1.06 |
---|---|
High | 1.11 |
Low | 1.06 |
Bid | 1.09 |
Offer | 1.18 |
Previous close | 1.05 |
Average volume | 91.67 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jul 01 2022.
More ▼